Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients

NCT02755844
completedphase_1

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

NCT01661400
completedphase_2

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

NCT02838342
terminatedphase_2

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02117024
terminatedphase_2

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

NCT01910870

Clinical Trials (5)

Showing 5 of 5 trials
NCT02755844Phase 1

Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients

Completed
NCT01661400Phase 1

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

Completed
NCT02838342Phase 2

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

Completed
NCT02117024Phase 2

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Terminated
NCT01910870Phase 2

Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5